You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆瑞醫藥(600276.SH):SHR1459片獲批藥物臨牀試驗
格隆匯 12-20 16:58

格隆匯12月20日丨恆瑞醫藥(600276.SH)公佈,近日,公司收到國家藥品監督管理局核准簽發關於SHR1459片的《藥物臨牀試驗批准通知書》,將於近期開展臨牀試驗。

SHR1459屬於BTK選擇性小分子抑制劑。臨牀前研究表明,SHR1459在體外顯示出很強的激酶選擇性,在體外和體內實驗中均顯示出良好的抗B細胞淋巴瘤活性,毒理結果也表明SHR1459的動物耐受性良好,預計對B細胞淋巴瘤將具有很高的臨牀應用價值。

經查詢EvaluatePharma數據庫,2020年Ibrutinib、Acalabrutinib、澤布替尼全球銷售額約為71.76億美元。截至目前,SHR1459相關研發項目累計已投入研發費用約為1.1636億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account